ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Part One Of A Two-Part Interview With NCI Director Harold Varmus

July 22, 2011

NCCS Networker Volume 4 Issue 1, Winter 1990

January 13, 1990

In Brief: Karmanos Institute Names Four To Faculty; $1.5M Donated To Kaplan Cancer Center

September 11, 1998

Community Cancer Control Program Survives Schmidt Criticism; NCAB Votes To Continue

October 17, 1975

In Brief: Chance for Rauscher Pay Increase Bill Seems Diminishing, But Schmidt Remains Confident

April 30, 1976

NCI Facing Its Most Serious Fiscal Crisis With Order To Cut 1982 Budget 12 Percent; NCAB Objects To Reagan

October 16, 1981